LSD1：改变肿瘤微环境和增强免疫检查点治疗的新兴面孔。
LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy.
机构信息
Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, China.
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
出版信息
J Biomed Sci. 2023 Jul 31;30(1):60. doi: 10.1186/s12929-023-00952-0.
Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.
肿瘤微环境（TME）中各种细胞的失调导致免疫抑制功能和侵袭性肿瘤生长。与免疫检查点阻断（ICB）联合使用，表观遗传修饰靶向药物作为有吸引力的癌症治疗方法正在出现。赖氨酸特异性去甲基化酶 1（LSD1）是一种修饰组蛋白和非组蛋白的蛋白质，已知它会影响多种生理过程。LSD1 的功能障碍导致预后不良、患者生存不良、耐药性、免疫抑制等，使其成为癌症治疗的潜在表观遗传靶点。本文综述了 LSD1 如何调节 TME 中不同细胞的行为，并强调了 LSD1 抑制剂与 ICB 治疗联合使用在未来癌症研究中的潜在应用。
Zotero 插件